In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

adding that they round out GSK’s drug-based efforts to treat the diseases. “We feel we are in a good place because we know ...

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price ...

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and ...

and we knew we could put trust in Kuehne+Nagel's global experience in handling healthcare and consumer goods." Matthias Blan, Managing Director, Türkiye, Kuehne+Nagel adds: "We are excited to ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s intraday trade. The stock rose after the company reported its second quarter ...

Wednesday, GSK Plc (NYSE:GSK) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts estimated sales of ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.1 at the end of 2023 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

Consumer healthcare requires the skills and talent closer to fast ... more focused and pursuing strategies based on innovative prescription drug portfolios. GSK, Johnson & Johnson, Pfizer, Novartis ...

The acquisition of CMG1A46 is a strategic move to address the diverse manifestations of lupus and the ongoing burden it places on patients. Credit: Indypendenz ...